Bernstein Upgrades J&J (JNJ) to Outperform; Sees Pharma Pipeline Adding $6B in Sales by 2015

May 25, 2011 7:52 AM EDT
Get Alerts JNJ Hot Sheet
Price: $111.80 -1.85%

Rating Summary:
    9 Buy, 16 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 18 | Down: 19 | New: 11
Trade JNJ Now!
Join SI Premium – FREE
Bernstein's Derrick Sung upgraded shares of Johnson & Johnson (NYSE: JNJ) from Market Perform to Outperform Wednesday morning. The analyst also boosted Bernstein's price target on the stock by 24 percent from $63 to $78.

The analyst believes Johnson & Johnson's Pharma pipeline is attractive and starting to contribute to sales. Sung argues the unit could eventual drive $6 billion in new product sales by 2015.

Shares of Johnson & Johnson are up 0.5 percent to $66.13 this morning. Bernstein's new price target implies potential upside of nearly 18 percent from where the stock is trading Wednesday.

For more ratings news on Johnson & Johnson click here and for the rating history of Johnson & Johnson click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Hot Upgrades, Upgrades

Add Your Comment